Kornimate/medical-research-clean huggingface dataset:
metabolic consequences of heterozygous hereditary fructose intolerance

Conditions: Hereditary Fructose Intolerance; Fructose Metabolism, Inborn Errors; Glucose Metabolism Disorders

Summary: background: high fructose intake increases blood lactate, triglyceride and uric acid concentrations. uric acid may contribute to insulin resistance and dyslipidemia in the general population. in patients with hereditary fructose intolerance fructose consumption is associated with acute hypoglycemia, renal tubular acidosis, and hyperuricemia. objective: we investigated whether asymptomatic carriers for hereditary fructose intolerance (hfi) would have a higher sensitivity to adverse effects of fructose than the general population. design: eight subjects heterozygous for hfi (hhfi; 4 males, 4 females) and eight controls received for 7 days a low fructose diet and on the eighth day ingested a test meal calculated to provide 25% of basal energy requirement containing labeled fructose (13c fructose 0.35 g/kg), protein (0.21 g/kg) and lipid (0.22 g/kg). total fructose oxidation, total endogenous glucose production (by 6,6-2h2-glucose dilution), carbohydrate and lipid oxidation, lipids, uric acid, lactate, creatinine, urea and amino acids were monitored for 6 hours.


Eligibility criteria:
inclusion criteria: * 8 healthy volunteers (4 male, 4 female) parents of a child with hereditary fructose intolerance with aldob with heterozygous mutation of aldob gene * 8 healthy volunteers (4 male, 4 female), healthy with no mutation of aldob gene exclusion criteria: * fasting glycemia \> 7.0 mmol/l * fasting total triglycerides \> 4.0 mmol/l * chronic renal insufficiency (egfr ≤ 50 ml/min) * anemia (ferritin \< 20 ug/l, hemoglobin \< 13.5 ou 12.5 g/dl) * drugs * pregnancy
post covid-19 interstitial lung disease: a study of genetic and environmental interactions

Conditions: Pulmonary Fibrosis; COVID-19 Pneumonia

Summary: this study aims to understand why some people who have had covid-19 develop scarring of the lungs and why some people recover more quickly than others.

a large number of people diagnosed with covid-19 suffer from long term symptoms, predominantly breathlessness and fatigue whether or not they were admitted to hospital. while there are a number of causes of long-term breathlessness following covid-19 one of the most common, and potentially concerning with regards to long term prognosis is interstitial lung disease. the fibrogenic potential of sars-cov-2 is currently unknown but is predicted to be substantial based on the experience of previous coronavirus outbreaks and emerging data from this pandemic. the investigators do not yet understand how scarring occurs following sars-cov-2, nor why there is resolution in some individuals and persistent or progressive disease in others. the investigators therefore plan to undertake bronchoscopy (camera test into the lungs) to examine for changes in the way the cells lining the lung behave, using genetics, and differences in the bacteria living in the airways in patients whom have developed scarring following covid-19.

Eligibility criteria:
inclusion criteria: * evidence of sars-cov-2 pcr/seropositive * presence of interstitial lung disease on ct * participant is willing and able to give informed consent for participation in the study * aged 18 years or above exclusion criteria: * confirmed ild diagnosis prior to march 2020 * patients with co-morbid disease that in the opinion of the investigators gives them an expected life expectancy of less than one year will be excluded from the study. * use of steroids at baseline visit
comparison of hemostatic agent to suture in terms of hemostatic function and preservation of ovarian function

Conditions: Benign Ovarian Cyst

Summary: this study aims to evaluate the efficacy of preservation of ovarian function, hemostasis, and safety of a hemostatic agent versus suturing during laparoscopic ovarian cystectomy for ovarian endometriosis.

in women with endometrioma who plan to undergo laparoscopic ovarian cystectomy, surgical technique can influence postoperative ovarian function because of removal of normal ovarian tissue with ovarian cyst and damage to ovarian tissue during bleeding control after stripping of endometrioma. this study is designed to compare hemostatic sealant to suturing in terms of hemostatic function, safety and preservation of ovarian function. ovarian function of all patients will be evaluated on pre op, post op 12 weeks, post op 48 weeks by measuring amh and ovarian volume. and hemostatic function will be evaluated by measuring serum hemoglobin, blood loss during operation, etc.

Eligibility criteria:
inclusion criteria: * informed consent. * age: 19-45 year-old women * american society of anesthesiologists physical status classification 1 or 2 * plan of laparoscopic ovarian cystectomy for unilateral or bilateral ovarian endometriosis diagnosed by ultrasonography * regular menstruation every 21-45 days exclusion criteria: * no 'ovarian' endometriosis * suspicious disease of ovarian malignancy * age: 18 and younger, 46 and older * pregnancy or breastfeeding. * lower than 0.05 ng/ml of serum anti-mullerian hormone level * hormonal therapy within recent 3 months * considered as inappropriate by the researcher's judgment.

Keywords: endometriosis endometrioma ovarian cystectomy ovarian function ovarian reserve hemostatic agent suture
randomized control trial of an animal-assisted intervention with adjudicated youth

Conditions: Conduct Disorder; Depression; Anxiety

Summary: the project involves testing the efficacy of an animal-assisted intervention (aai). the aai consists of a 10-week program in which adjudicated adolescents train shelter dogs and will be compared to a dog walking control group matched for educational content and dog contact time. the investigators expect that the aai will result in improved empathy skills and that dog attachment will explain these findings. the investigators also explore the extent to which the aai will improve internalizing and externalizing symptoms in these adolescents.

adjudicated adolescents (i.e., teens who have committed criminal offenses and are incarcerated in juvenile detention centers) have deficits in emotion regulation, including empathy skills, and are at risk for a host of poor outcomes including repeat offenses, internalizing symptoms (e.g., depression, anxiety), externalizing symptoms (e.g., lying, truancy, fighting). many of these problems stem from a lack of secure attachment to parents and peers. there is a need for novel and innovative programs to help these teens develop more secure attachments and better empathy skills to prevent poor outcomes. one type of intervention is animal-assisted interventions such as dog training programs. these programs appear to build empathy skills in at-risk youth, which may translate into better peer relations, less psychological distress, and less recidivism. the goal of this study is to test an existing animal-assisted intervention program that is already being used in juvenile detention centers to determine whether it is efficacious in improving adjudicated adolescents' empathy skills and psychological symptoms through building a secure attachment to the training dog.

Eligibility criteria:
inclusion criteria: * must be a resident of participating juvenile justice center in michigan exclusion criteria: * none

Keywords: animal-assisted intervention adjudicated adolescents empathy
explain -fragile x registry: an explorative longitudinal study for characterization, treatment pathways and patient-related outcomes

Conditions: Fragile-X Syndrome

Summary: this prospective observational study (registry) on fragile x syndrome (fxs) is designed to evaluate characteristics, management and patient and caregiver-related outcomes the quality of life of families and patients with fxs and to collect epidemiological and health economic data. * explain will report current and comprehensive data onepidemiology data on fragile x syndrome * characterisation of the phenotype of fxs patients * description of patient characteristics (demographics, family history, comorbidity, education, working situations, care situations, insurance status) * documentation of therapeutic interventions * recording and assessment of psychosocial parameters (possibly also inclusion of family members, carers) * quality of life of the carer and if possible the patient * health economic parameters and consumption of resources


Eligibility criteria:
inclusion criteria: * patients with fxs as confirmed by genetic testing exclusion criteria: * none * other protocol-defined inclusion/exclusion criteria may apply

Keywords: fragile-x syndrome registry non-interventional trial patient-related outcome study drug utilization effectiveness treatment patterns patient characteristics under real life conditions quality of life economics
a randomized phase ii/genomic trial of two chemotherapy regimens in patients with resected pancreatic adenocarcinoma

Conditions: Pancreatic Adenocarcinoma

Summary: determine the relapse-free survival of resected pancreatic cancer patients following two novel regimens with activity in advanced disease.

this trial is a randomized phase ii study of folfirinox versus gemcitabine/abraxane in patients with completely resected pancreatic cancer (stages i-iii). patients will receive eight weeks of chemotherapy, then 5-fu/radiation, then another 8 weeks.

Eligibility criteria:
inclusion criteria: * patients must have histologically or cytologically confirmed evidence of pancreatic carcinoma. * patients must have had all gross disease resected (r0 or r1 resection, patients who underwent an r2 resection are not eligible). * patients must have had no prior chemotherapy or radiation therapy for pancreatic cancer. * age \> 18 years. * patient must have eastern cooperative oncology group (ecog) performance status of 0-2. * patients must have normal organ and marrow function measured within 2 weeks, prior to registration as follows: absolute neutrophil count (anc) \> 1,500/µl platelets \> 100,000/µl total bilirubin less than 2-fold upper limit of normal (uln) aspartate aminotransferase (ast)/alanine aminotransferase (alt)\ 60ml/min for patients with creatinine levels above institutional normal. * patients must be \> 4 weeks and \< 12 weeks post-surgery at time of study registration. * women of childbearing potential and sexually active males are strongly advised to use appropriate contraceptive measures. * women must not be pregnant or breast-feeding. exclusion criteria: * patients receiving any other investigational agents. * patients with known metastases. * patients with wounds that have not fully healed.

Keywords: patients with resected
maintenance gabapentin to prolong pregnancy.

Conditions: Preterm Labor, Premature Birth

Summary: this is a pilot study to evaluate the tolerability and effects of maintenance gabapentin therapy on the rate of premature birth in women who have had preterm labor.


Eligibility criteria:
eligibility criteria: 1. healthy 18-45 year old female with singleton pregnancy, 20-34 weeks gestation, without ruptured membranes. 2. preterm labor defined as regular uterine contractions of at least 6/hour for ≥ 1 hour with ≥ 1cm of cervical dilation or ≤ 2.5cm cervical length or any documented cervical change from the initial pelvic exam. 3. cervical dilation not more than 4cm. 4. initiation of a tocolytic agent (e.g. magnesium sulfate, nifedipine, indomethacin) within the previous 72 hours. 5. pregnancy not conceived through in-vitro fertilization (ivf) due to the known higher rates of congenital defects associated with this procedure.30 6. no placenta praevia or abruptio placentae or cervical cerclage. 7. no intra-uterine growth restriction or non-reassuring fetal status. 8. no known serious fetal malformations. 9. no chorioamnionitis or medical/psychiatric/substance abuse comorbidity that may complicate the pregnancy or interfere with the subject's ability to comply with study procedures in the opinion of dr. guttuso or the subject's obstetrician. 10. no history of suicide attempt. no suicidal thoughts over past 6 months. 11. not currently receiving gabapentin, pregabalin, progesterone or a known teratogenic medication and no known allergy to gabapentin therapy.

Keywords: preterm labor, premature birth, gabapentin
serum markers as a bioassay for unipolar depression

Conditions: Major Depression

Summary: the goal of the study is to validate a biomarker assay for unipolar depression based on serum proteins involved in inflammation, metabolism, and stress response. the study will compare patients with a current major depressive episode to individuals with no history of depression. the hypothesis is that the assay can serve as a diagnostic tool that would be more objective than standard diagnostic questionnaires.


Eligibility criteria:
inclusion criteria (depressed): * aged 18 to 60. * meets dsm-iv criteria for unipolar major depression, either single or recurrent. * 21 item hamilton depression rating scale score greater than 18. * capable of providing informed consent. * has an established residence and phone number. exclusion criteria: * meets dsm-iv criteria for bipolar disorder, schizophrenia, schizoaffective disorder or other major axis i psychiatric disorders (except for depression and phobia per above). * addison's disease, cushing's disease, or other known dysfunction of the hpa-cortisol axis. * rheumatoid arthritis, lupus, or other condition associated with increased inflammation. * regular use of non-steroidal anti-inflammatory medications, steroids, or other medications know to interact with the inflammatory process of the hpa axis. * a medical condition or regular use of a mediation, which i the opinion of the investigator is likely to influence the inflammatory or hpa responses. * pregnancy. * meets dsm-iv criteria for substance abuse or dependence in the last month. * regular cigarette smoking. * history of fainting or other significant adverse event during blood drawing in the past.

Keywords: biomarker depression blood test
a study of al2846 on tolerance and pharmacokinetics

Conditions: Advanced Cancer

Summary: a study of al2846,a c-met/hepatocyte growth factor tyrosine kinase inhibitor,in patients with advanced cancer.

to study the pharmacokinetic characteristics of al2846 in the human body; to recommend a reasonable dose and indication for subsequent research.

Eligibility criteria:
inclusion criteria: * histological documentation of advanced solid tumors（especially hepatocellular carcinoma and lung cancer ）,at least one measurable lesion (by recist1.1) * lack of the standard treatment or treatment failure * 18-65 years,ecog ps:0-1,life expectancy of more than 3 months * 30 days or more from the last cytotoxic therapy * main organs function is normal * women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating；man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped * patients should participate in the study voluntarily and sign informed consent exclusion criteria: * patients suffering from other malignancies currently or ever, except for cured cervical carcinoma in situ, non-melanoma skin cancers * patients with factors that could affect oral medication (such as dysphagia，chronic diarrhea, intestinal obstruction etc.) * patients participated in other anticancer drug clinical trials within 4 weeks or patients participating in other clinical trials now * blood pressure unable to be controlled ideally by one drug(systolic pressure≥140 mmhg，diastolic pressure≥90 mmhg); patients with grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including male qtc≥450ms,female qtc≥470ms) and patients with grade 1 or higher congestive heart failure (nyha classification) * urine protein ≥ ++，and 24-hour urinary protein excretion\>1.0 g confirmed * patients with non-healing wounds or fractures * patients with drug abuse history and unable to get rid of or patients with mental disorders * history of immunodeficiency * patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment
malnutrition is a severe health issue for cancer patients. this study examines how preoperative nutritional status affects postoperative delirium in patients undergoing major abdominal surgery for gynecological and gastrointestinal tumors.

Conditions: Surgery; Malnutrition; Delirium, Postoperative; Abdominal Neoplasm

Summary: the world health organization (who) identifies malnutrition as a significant public health threat. it is a common issue among cancer patients due to various factors. specific nutrient deficiencies can lead to severe cognitive problems. this study aims to evaluate the impact of preoperative nutritional status on the frequency of postoperative delirium. additionally, we will compare different parameters that can be used to diagnose preoperative malnutrition. we included a total of 120 patients aged over 18 years, classified as asa i-iv, who were undergoing major abdominal surgery for gynecological or gastrointestinal tumors and were expected to remain in the postoperative care unit for more than 24 hours. the patients' preoperative scores, albumin levels, prealbumin levels, and other relevant data were recorded. in the first 24 hours post-surgery, delirium was assessed using the ramsay sedation scale and the confusion assessment method for the intensive care unit (cam-icu).


Eligibility criteria:
inclusion criteria: * asa i-iv * over 18 years of age * undergoing major abdominal surgery for gynecological and gis tumor * expected to stay in postoperative care unit for more than 24 hours exclusion criteria: * under age 18. * patients scheduled for emergency surgery, pregnancy, who want to withdraw from postoperative work. * patients with dementia, alzheimer, psychiatric illness, illiterate people. * patients with speech, vision and hearing problems. * patients with a history of alcoholism. * patients who need postoperative mechanical ventilation support (patients who develop heart or respiratory failure due to copd, heart failure, pulmonary embolism and similar reasons)
real-world effectiveness of ustekinumab in participants suffering from inflammatory bowel disease (crohn's disease or ulcerative colitis) with extra-intestinal manifestations or immune-mediated inflammatory diseases

Conditions: Crohn Disease; Colitis, Ulcerative

Summary: the purpose of this study is to assess the effectiveness of ustekinumab on extra-intestinal manifestations (eims) and immune-mediated inflammatory diseases (imids) associated with inflammatory bowel disease (ibd) (both crohn's disease \[cd\] and ulcerative colitis \[uc\]).


Eligibility criteria:
inclusion criteria: * with a confirmed diagnosis of cd or uc * with at least one eim of interest (cutaneous: pyoderma gangrenosum; erythema nodosum, articular: axial spondyloarthritis and peripheral spondyloarthritis with and without psoriasis, dactylitis, enthesitis; ocular: uveitis) and/or at least one imids of interest (cutaneous: psoriasis, atopic dermatitis, hidradenitis suppurativa), suspected or confirmed, that is active at the time of screening * starting ustekinumab as a biologic therapy for cd or uc treatment independently of their enrollment into the study * using ustekinumab according to the smpc * only for participants with cd: has had an inadequate response with or lost response to or be intolerant to conventional therapy including azathioprine, 6-mercaptopurine or corticosteroids or; at least one tumor necrosis factor (tnf) blocker (adalimumab, infliximab). only for participants with uc: have had an inadequate response with, lost response to, or were intolerant to either conventional including azathioprine, 6-mercaptopurine or corticosteroids or a biologic exclusion criteria: * participants suffering from a psoriasis induced by a biological therapy at inclusion (including tnf blocker) or participant presenting an active psoriasis that was diagnosed before the time of inflammatory bowel disease (ibd) diagnosis * participants currently enrolled in an investigational study (or have been in the past 2 months) or are unwilling or not able to understand or provide their consent
evaluation of optimal time of methimazole discontinuation before radio-iodine therapy in hyperthyroid grave's patients

Conditions: Graves Disease

Summary: iodine therapy is the best treatment for graves disease.most patients receive methimozale prior to radio-iodine treatment. this may decrease treatment response to iodine therapy. some physicians advice to discontinue methimazole 3 days before radioiodine therapy and others prefer longer off - methimazole period which bothers most patients. this study aimed to evaluate optimum time for methimazole discontinuation in graves disease.


Eligibility criteria:
inclusion criteria: * age 18-65 * graves disease(tsh\<0.1 \&increased ft4 \& positive tsi * one or more bartlena criteria for radio-iodine therapy * 24 hour raiu\>25% * euthyroidism after methimazole treatment exclusion criteria: * pregnancy or lactation * moderate or severe graves ophthalmopathy * chf or coronary heart disease * palpable thyroid nodule * lithium or amiodarone or lugol or ipodate treatment * recent imaging with contrast agent * very large goiter(more than 150 gram)

Keywords: hyperthyroidism radio-iodine i-131 methimazole graves disease
fruquintinib-based treatment for refractory bone and soft tissue sarcomas after several lines of tkis' resistance

Conditions: Bone Sarcoma; Soft Tissue Sarcoma; Refractory Tumor

Summary: this multicenter retrospective study assessed the efficacy and safety of fruquintinib-based treatment in patients with refractory bone and soft tissue sarcomas after several lines of tkis' resistance.

the short-lived duration of disease control and secondary drug resistance have posed a threat to the effect of tkis. fruquintinib is a novel tki with a high selectivity of vegfr-1,2,3 without metabolism by liver enzymes and was approved for application in mcrc. serious drug resistance and the unique characteristics of fruquintinib have prompted us to verify whether this drug can reverse tkis' resistance at a higher dose.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed bone or soft tissue sarcomas; 2. progressed after several lines of therapy; 3. previously treated with other tkis before fruquintinib; 4. received fruquintinib-based treatment; 5. measurable lesions according to the response evaluation criteria for solid tumors (recist) version1.1; 6. eastern cooperative oncology group (ecog) performance status ≤3 exclusion criteria: 1. failure to complete regular follow-up after administration. 2. discontinued the fruquintinib-based treatment due to neither progression nor unacceptable toxicity.

Keywords: fruquintinib osteosarcoma ewing sarcoma soft tissue sarcomas tkis